CEP 37440

Drug Profile

CEP 37440

Alternative Names: CEP-37440

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cephalon
  • Developer Teva Pharmaceutical Industries
  • Class Antineoplastics
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; PTK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO, Capsule)
  • 01 Dec 2015 Teva Pharmaceutical Industries completes a phase I trial for Solid tumours (Late-stage disease) in USA (NCT01922752)
  • 12 Aug 2013 Phase-I clinical trials in Solid tumours (late-stage disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top